Bumetanide Oral Liquid Formulation for the Treatment of Children and Adolescents with Autism Spectrum Disorder: Design of Two Phase III Studies (SIGN Trials) / Véronique CRUTEL in Journal of Autism and Developmental Disorders, 51-8 (August 2021)  

Public ISBD [article]  inJournal of Autism and Developmental Disorders > 51-8 (August 2021) . - p.2959-2972 Titre : Bumetanide Oral Liquid Formulation for the Treatment of Children and Adolescents with Autism Spectrum Disorder: Design of Two Phase III Studies (SIGN Trials) Type de document : texte imprimé Auteurs : Véronique CRUTEL, Auteur ; Estelle LAMBERT, Auteur ; Pierre-François PÉNÉLAUD, Auteur ; Cristina ALBARRÁN SEVERO, Auteur ; Joaquin FUENTES, Auteur ; Antoine ROSIER, Auteur ; Amaia HERVAS, Auteur ; Stéphane MARRET, Auteur ; Guiomar OLIVEIRA, Auteur ; Mara PARELLADA, Auteur ; Simon KYAGA, Auteur ; Sylvie GOUTTEFANGEAS, Auteur ; Marianne BERTRAND, Auteur ; Denis RAVEL, Auteur ; Bruno FALISSARD, Auteur Article en page(s) : p.2959-2972 Langues : Anglais (eng) Mots-clés : Adolescent  Autism Spectrum Disorder/drug therapy  Bumetanide/administration & dosage/therapeutic use  Child  Child, Preschool  Double-Blind Method  Humans  Male  Research Design  Social Behavior  Treatment Outcome  Autism spectrum disorder  Bumetanide  Pediatrics  Randomized controlled trial  for Actelion, Allergan, Almirall, Astellas, AstraZeneca, Bayer, Biotronik, BMS,  Boehringer Ingelheim, Daiichi- Sankyo, Eli Lilly, Genzyme, Gilead, Grunenthal, GSK,  HRA, Janssen, Lundbeck, MSD, Novartis, Otsuka, Pierre Fabre, Roche, Sanofi, Servier,  Stallergene, UCB, ViiV. JF has received research support from Servier and  AIMS-2-Trials project ID 777394. DR is an employee of Neurochlore. GO, SM, AR, AH,  and MP report no conflict of interest. Index. décimale : PER Périodiques Résumé : There are currently no approved pharmacological treatments to improve social reciprocity and limit repetitive and rigid behaviors in autism spectrum disorder (ASD). We describe the design of two Phase III studies evaluating the efficacy/safety of bumetanide oral liquid formulation in ASD. These are international, multicenter, randomized, double-blind, placebo-controlled studies in children and adolescents with ASD aged 7 to 17 years (n = 200; study 1), or younger children with ASD aged 2 to 6 years (n = 200; study 2). The primary endpoint of each is change in Childhood Autism Rating Scale 2 total raw score after 6 months. These studies could contribute to the first pharmacological treatment to improve social reciprocity and limit repetitive and rigid behaviors in children and adolescents with ASD. En ligne : http://dx.doi.org/10.1007/s10803-020-04709-8 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=453 [article] Bumetanide Oral Liquid Formulation for the Treatment of Children and Adolescents with Autism Spectrum Disorder: Design of Two Phase III Studies (SIGN Trials) [texte imprimé] / Véronique CRUTEL, Auteur ; Estelle LAMBERT, Auteur ; Pierre-François PÉNÉLAUD, Auteur ; Cristina ALBARRÁN SEVERO, Auteur ; Joaquin FUENTES, Auteur ; Antoine ROSIER, Auteur ; Amaia HERVAS, Auteur ; Stéphane MARRET, Auteur ; Guiomar OLIVEIRA, Auteur ; Mara PARELLADA, Auteur ; Simon KYAGA, Auteur ; Sylvie GOUTTEFANGEAS, Auteur ; Marianne BERTRAND, Auteur ; Denis RAVEL, Auteur ; Bruno FALISSARD, Auteur . - p.2959-2972. Langues : Anglais (eng) in Journal of Autism and Developmental Disorders > 51-8 (August 2021) . - p.2959-2972 Mots-clés : Adolescent  Autism Spectrum Disorder/drug therapy  Bumetanide/administration & dosage/therapeutic use  Child  Child, Preschool  Double-Blind Method  Humans  Male  Research Design  Social Behavior  Treatment Outcome  Autism spectrum disorder  Bumetanide  Pediatrics  Randomized controlled trial  for Actelion, Allergan, Almirall, Astellas, AstraZeneca, Bayer, Biotronik, BMS,  Boehringer Ingelheim, Daiichi- Sankyo, Eli Lilly, Genzyme, Gilead, Grunenthal, GSK,  HRA, Janssen, Lundbeck, MSD, Novartis, Otsuka, Pierre Fabre, Roche, Sanofi, Servier,  Stallergene, UCB, ViiV. JF has received research support from Servier and  AIMS-2-Trials project ID 777394. DR is an employee of Neurochlore. GO, SM, AR, AH,  and MP report no conflict of interest. Index. décimale : PER Périodiques Résumé : There are currently no approved pharmacological treatments to improve social reciprocity and limit repetitive and rigid behaviors in autism spectrum disorder (ASD). We describe the design of two Phase III studies evaluating the efficacy/safety of bumetanide oral liquid formulation in ASD. These are international, multicenter, randomized, double-blind, placebo-controlled studies in children and adolescents with ASD aged 7 to 17 years (n = 200; study 1), or younger children with ASD aged 2 to 6 years (n = 200; study 2). The primary endpoint of each is change in Childhood Autism Rating Scale 2 total raw score after 6 months. These studies could contribute to the first pharmacological treatment to improve social reciprocity and limit repetitive and rigid behaviors in children and adolescents with ASD. En ligne : http://dx.doi.org/10.1007/s10803-020-04709-8 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=453

Correction to: Bumetanide Oral Liquid Formulation for the Treatment of Children and Adolescents with Autism Spectrum Disorder: Design of Two Phase III Studies (SIGN Trials) / Véronique CRUTEL in Journal of Autism and Developmental Disorders, 51-8 (August 2021)  

Public ISBD [article]  inJournal of Autism and Developmental Disorders > 51-8 (August 2021) . - p.2973 Titre : Correction to: Bumetanide Oral Liquid Formulation for the Treatment of Children and Adolescents with Autism Spectrum Disorder: Design of Two Phase III Studies (SIGN Trials) Type de document : texte imprimé Auteurs : Véronique CRUTEL, Auteur ; Estelle LAMBERT, Auteur ; Pierre-François PÉNÉLAUD, Auteur ; Cristina ALBARRÁN SEVERO, Auteur ; Joaquin FUENTES, Auteur ; Antoine ROSIER, Auteur ; Amaia HERVAS, Auteur ; Stéphane MARRET, Auteur ; Guiomar OLIVEIRA, Auteur ; Mara PARELLADA, Auteur ; Simon KYAGA, Auteur ; Sylvie GOUTTEFANGEAS, Auteur ; Marianne BERTRAND, Auteur ; Denis RAVEL, Auteur ; Bruno FALISSARD, Auteur Article en page(s) : p.2973 Langues : Anglais (eng) Index. décimale : PER Périodiques En ligne : http://dx.doi.org/10.1007/s10803-020-04822-8 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=453 [article] Correction to: Bumetanide Oral Liquid Formulation for the Treatment of Children and Adolescents with Autism Spectrum Disorder: Design of Two Phase III Studies (SIGN Trials) [texte imprimé] / Véronique CRUTEL, Auteur ; Estelle LAMBERT, Auteur ; Pierre-François PÉNÉLAUD, Auteur ; Cristina ALBARRÁN SEVERO, Auteur ; Joaquin FUENTES, Auteur ; Antoine ROSIER, Auteur ; Amaia HERVAS, Auteur ; Stéphane MARRET, Auteur ; Guiomar OLIVEIRA, Auteur ; Mara PARELLADA, Auteur ; Simon KYAGA, Auteur ; Sylvie GOUTTEFANGEAS, Auteur ; Marianne BERTRAND, Auteur ; Denis RAVEL, Auteur ; Bruno FALISSARD, Auteur . - p.2973. Langues : Anglais (eng) in Journal of Autism and Developmental Disorders > 51-8 (August 2021) . - p.2973 Index. décimale : PER Périodiques En ligne : http://dx.doi.org/10.1007/s10803-020-04822-8 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=453

A full-body interactive videogame used as a tool to foster social initiation conducts in children with Autism Spectrum Disorders / Maria Angeles MAIRENA in Research in Autism Spectrum Disorders, 67 (November 2019)  

Public ISBD [article]  inResearch in Autism Spectrum Disorders > 67 (November 2019) . - p.101438 Titre : A full-body interactive videogame used as a tool to foster social initiation conducts in children with Autism Spectrum Disorders Type de document : texte imprimé Auteurs : Maria Angeles MAIRENA, Auteur ; Joan MORA-GUIARD, Auteur ; Laura MALINVERNI, Auteur ; Vanesa PADILLO, Auteur ; Lilia VALERO, Auteur ; Amaia HERVAS, Auteur ; Narcis PARES, Auteur Article en page(s) : p.101438 Langues : Anglais (eng) Mots-clés : Autism Spectrum Disorder  Social skills  Full-body interaction  Observational scale Index. décimale : PER Périodiques Résumé : Background Game-based interventions that involve the use of technology have shown to facilitate motivation and learning processes in children with Autism Spectrum Disorders (ASD). The purpose of this observational study project was to conduct a feasibility study to compare the amount of social initiation conducts performed during a full-body interaction videogame versus the amount of social initiation conducts occurred during a free-play activity in children with ASD. We hypothesized that the videogame could elicit a higher number of these conducts and therefore could be proposed as a tool to promote social initiation skills. Method A total of 15 children (ages 4–6) participated in four sessions with two sections: playing with the videogame Pico’s Adventure and free play time. Social skills conducts were codified according to an observational scale. Results Results show that the videogame elicited more social initiation conducts than free play in children with ASD when they were playing alone or playing with a peer. Furthermore, it showed to be as effective as free play in promoting social initiation while playing with parents. The videogame was also effective in reducing repetitive behaviors and increasing gestures. Conclusions Considering all these results, the videogame could be considered as an appropriate tool to foster social behaviors but future work is needed in order to obtain further data that supports this hypothesis. Finding new attractive types of treatment would be useful to complement more traditional therapies. En ligne : https://doi.org/10.1016/j.rasd.2019.101438 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=405 [article] A full-body interactive videogame used as a tool to foster social initiation conducts in children with Autism Spectrum Disorders [texte imprimé] / Maria Angeles MAIRENA, Auteur ; Joan MORA-GUIARD, Auteur ; Laura MALINVERNI, Auteur ; Vanesa PADILLO, Auteur ; Lilia VALERO, Auteur ; Amaia HERVAS, Auteur ; Narcis PARES, Auteur . - p.101438. Langues : Anglais (eng) in Research in Autism Spectrum Disorders > 67 (November 2019) . - p.101438 Mots-clés : Autism Spectrum Disorder  Social skills  Full-body interaction  Observational scale Index. décimale : PER Périodiques Résumé : Background Game-based interventions that involve the use of technology have shown to facilitate motivation and learning processes in children with Autism Spectrum Disorders (ASD). The purpose of this observational study project was to conduct a feasibility study to compare the amount of social initiation conducts performed during a full-body interaction videogame versus the amount of social initiation conducts occurred during a free-play activity in children with ASD. We hypothesized that the videogame could elicit a higher number of these conducts and therefore could be proposed as a tool to promote social initiation skills. Method A total of 15 children (ages 4–6) participated in four sessions with two sections: playing with the videogame Pico’s Adventure and free play time. Social skills conducts were codified according to an observational scale. Results Results show that the videogame elicited more social initiation conducts than free play in children with ASD when they were playing alone or playing with a peer. Furthermore, it showed to be as effective as free play in promoting social initiation while playing with parents. The videogame was also effective in reducing repetitive behaviors and increasing gestures. Conclusions Considering all these results, the videogame could be considered as an appropriate tool to foster social behaviors but future work is needed in order to obtain further data that supports this hypothesis. Finding new attractive types of treatment would be useful to complement more traditional therapies. En ligne : https://doi.org/10.1016/j.rasd.2019.101438 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=405

Le genre : un facteur protecteur dans l'expression phénotypique de l'autisme ? / Amaia HERVAS in Bulletin Scientifique de l'arapi (Le), 36 (Hiver 2015)

Public ISBD [article]  inBulletin Scientifique de l'arapi (Le) > 36 (Hiver 2015) . - p.43-48 Titre : Le genre : un facteur protecteur dans l'expression phénotypique de l'autisme ? Type de document : texte imprimé Auteurs : Amaia HERVAS, Auteur ; Laetitia ROCHE, Auteur Année de publication : 2015 Article en page(s) : p.43-48 Langues : Français (fre) Index. décimale : PER Périodiques Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=284 [article] Le genre : un facteur protecteur dans l'expression phénotypique de l'autisme ? [texte imprimé] / Amaia HERVAS, Auteur ; Laetitia ROCHE, Auteur . - 2015 . - p.43-48. Langues : Français (fre) in Bulletin Scientifique de l'arapi (Le) > 36 (Hiver 2015) . - p.43-48 Index. décimale : PER Périodiques Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=284

Lack of replication of previous autism spectrum disorder GWAS hits in European populations / Bàrbara TORRICO in Autism Research, 10-2 (February 2017)  

Public ISBD [article]  inAutism Research > 10-2 (February 2017) . - p.202-211 Titre : Lack of replication of previous autism spectrum disorder GWAS hits in European populations Type de document : texte imprimé Auteurs : Bàrbara TORRICO, Auteur ; Andreas G. CHIOCCHETTI, Auteur ; Elena BACCHELLI, Auteur ; Elisabetta TRABETTI, Auteur ; Amaia HERVAS, Auteur ; Barbara FRANKE, Auteur ; Jan K. BUITELAAR, Auteur ; Nanda N. ROMMELSE, Auteur ; Afsheen YOUSAF, Auteur ; Eftichia DUKETIS, Auteur ; Christine M. FREITAG, Auteur ; Rafaela CABALLERO-ANDALUZ, Auteur ; Amalia MARTINEZ-MIR, Auteur ; Francisco G. SCHOLL, Auteur ; Marta RIBASES, Auteur ; ITAN, Auteur ; Agatino BATTAGLIA, Auteur ; Giovanni MALERBA, Auteur ; Richard DELORME, Auteur ; Marion BENABOU, Auteur ; Elena MAESTRINI, Auteur ; Thomas BOURGERON, Auteur ; Bru CORMAND, Auteur ; Claudio TOMA, Auteur Article en page(s) : p.202-211 Langues : Anglais (eng) Mots-clés : genome-wide association study  replication  autism spectrum disorder  European populations  MACROD2  SEMA5A  MSNP1 Index. décimale : PER Périodiques Résumé : Common variants contribute significantly to the genetics of autism spectrum disorder (ASD), although the identification of individual risk polymorphisms remains still elusive due to their small effect sizes and limited sample sizes available for association studies. During the last decade several genome-wide association studies (GWAS) have enabled the detection of a few plausible risk variants. The three main studies are family-based and pointed at SEMA5A (rs10513025), MACROD2 (rs4141463) and MSNP1 (rs4307059). In our study we attempted to replicate these GWAS hits using a case-control association study in five European populations of ASD patients and gender-matched controls, all Caucasians. Results showed no association of individual variants with ASD in any of the population groups considered or in the combined European sample. We performed a meta-analysis study across five European populations for rs10513025 (1,904 ASD cases and 2,674 controls), seven European populations for rs4141463 (2,855 ASD cases and 36,177 controls) and five European populations for rs4307059 (2,347 ASD cases and 2,764 controls). The results showed an odds ratio (OR) of 1.05 (95% CI = 0.84–1.32) for rs10513025, 1.0002 (95% CI = 0.93–1.08) for rs4141463 and 1.01 (95% CI = 0.92–1.1) for rs4307059, with no significant P-values (rs10513025, P = 0.73; rs4141463, P = 0.95; rs4307059, P = 0.9). No association was found when we considered either only high functioning autism (HFA), genders separately or only multiplex families. Ongoing GWAS projects with larger ASD cohorts will contribute to clarify the role of common variation in the disorder and will likely identify risk variants of modest effect not detected previously. En ligne : http://dx.doi.org/10.1002/aur.1662 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=303 [article] Lack of replication of previous autism spectrum disorder GWAS hits in European populations [texte imprimé] / Bàrbara TORRICO, Auteur ; Andreas G. CHIOCCHETTI, Auteur ; Elena BACCHELLI, Auteur ; Elisabetta TRABETTI, Auteur ; Amaia HERVAS, Auteur ; Barbara FRANKE, Auteur ; Jan K. BUITELAAR, Auteur ; Nanda N. ROMMELSE, Auteur ; Afsheen YOUSAF, Auteur ; Eftichia DUKETIS, Auteur ; Christine M. FREITAG, Auteur ; Rafaela CABALLERO-ANDALUZ, Auteur ; Amalia MARTINEZ-MIR, Auteur ; Francisco G. SCHOLL, Auteur ; Marta RIBASES, Auteur ; ITAN, Auteur ; Agatino BATTAGLIA, Auteur ; Giovanni MALERBA, Auteur ; Richard DELORME, Auteur ; Marion BENABOU, Auteur ; Elena MAESTRINI, Auteur ; Thomas BOURGERON, Auteur ; Bru CORMAND, Auteur ; Claudio TOMA, Auteur . - p.202-211. Langues : Anglais (eng) in Autism Research > 10-2 (February 2017) . - p.202-211 Mots-clés : genome-wide association study  replication  autism spectrum disorder  European populations  MACROD2  SEMA5A  MSNP1 Index. décimale : PER Périodiques Résumé : Common variants contribute significantly to the genetics of autism spectrum disorder (ASD), although the identification of individual risk polymorphisms remains still elusive due to their small effect sizes and limited sample sizes available for association studies. During the last decade several genome-wide association studies (GWAS) have enabled the detection of a few plausible risk variants. The three main studies are family-based and pointed at SEMA5A (rs10513025), MACROD2 (rs4141463) and MSNP1 (rs4307059). In our study we attempted to replicate these GWAS hits using a case-control association study in five European populations of ASD patients and gender-matched controls, all Caucasians. Results showed no association of individual variants with ASD in any of the population groups considered or in the combined European sample. We performed a meta-analysis study across five European populations for rs10513025 (1,904 ASD cases and 2,674 controls), seven European populations for rs4141463 (2,855 ASD cases and 36,177 controls) and five European populations for rs4307059 (2,347 ASD cases and 2,764 controls). The results showed an odds ratio (OR) of 1.05 (95% CI = 0.84–1.32) for rs10513025, 1.0002 (95% CI = 0.93–1.08) for rs4141463 and 1.01 (95% CI = 0.92–1.1) for rs4307059, with no significant P-values (rs10513025, P = 0.73; rs4141463, P = 0.95; rs4307059, P = 0.9). No association was found when we considered either only high functioning autism (HFA), genders separately or only multiplex families. Ongoing GWAS projects with larger ASD cohorts will contribute to clarify the role of common variation in the disorder and will likely identify risk variants of modest effect not detected previously. En ligne : http://dx.doi.org/10.1002/aur.1662 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=303

Positive and negative parenting in conduct disorder with high versus low levels of callous–unemotional traits / Ruth PAULI in Development and Psychopathology, 33-3 (August 2021)  

Permalink

Sex differences in psychiatric comorbidity and clinical presentation in youths with conduct disorder / Kerstin KONRAD in Journal of Child Psychology and Psychiatry, 63-2 (February 2022)  

Permalink

Temporal and Geographical Variability of Prevalence and Incidence of Autism Spectrum Disorder Diagnoses in Children in Catalonia, Spain / Laura PEREZ-CRESPO in Autism Research, 12-11 (November 2019)  

Permalink

---

1 (1 - 8 / 8) Par page : 25 50 100 200